Amyloid and Tau PET Positivity in Progressive Agrammatic Aphasia and Apraxia of Speech
Journal of Alzheimer's Disease · 2023
DOI: 10.3233/jad-230912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Katerina A Tetzloff und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Aphasia, Apraxias. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS.
Abstract (Originalsprache)
Background
The agrammatic variant of primary progressive aphasia (PAA), primary progressive apraxia of speech (PPAOS), or a combination of both (AOS-PAA) are neurodegenerative disorders characterized by speech-language impairments and together compose the AOS-PAA spectrum disorders. These patients typically have an underlying 4-repeat tauopathy, although they sometimes show evidence of amyloid-β and tau deposition on PET, suggesting Alzheimer’s disease (AD). Given the growing number of pharmacologic treatment options for AD, it is important to better understand the incidence of AD pathology in these patients.
Objective
This study aimed to evaluate the frequency of amyloid-β and tau positivity in AOS-PAA spectrum disorders. Sixty-five patients with AOS-PAA underwent a clinical speech-language battery and PiB PET and flortaucipir PET imaging.
Methods
Global PiB PET standardized uptake value ratios (SUVRs) and flortaucipir PET SUVRs from the temporal meta region of interest were compared between patient groups. For 19 patients who had died and undergone autopsy, their PET and pathology findings were also compared.
Results
The results showed that although roughly half of the patients are positive for at least one biomarker, their clinical symptoms and biomarker status were not related, suggesting that AD is not the primary cause of their neurodegeneration. All but one patient in the autopsy subset had a Braak stage of IV or less, despite four being positive on tau PET imaging.
Conclusions
Inclusion criteria for clinical trials should specify clinical presentation or adjust the evaluation of such treatments to be specific to disease diagnosis beyond the presence of certain imaging biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, MN, USA.
- Department of Radiology, Mayo Clinic, Rochester, MN, USA.
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Förderung
- NIDCD NIH HHS
Zitieren
APA
Tetzloff, K. A., Duffy, J. R., Clark, H. M., Pham, N. T. T., Machulda, M. M., Botha, H., Jack, C. R., Dickson, D. W., Lowe, V. J., Josephs, K. A., Whitwell, J. L., & Utianski, R. L. (2023). Amyloid and Tau PET Positivity in Progressive Agrammatic Aphasia and Apraxia of Speech. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-230912
Vancouver
Tetzloff KA, Duffy JR, Clark HM, Pham NTT, Machulda MM, Botha H, et al. Amyloid and Tau PET Positivity in Progressive Agrammatic Aphasia and Apraxia of Speech. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-230912
BibTeX
@article{Tetzloff2023,
author = {Tetzloff, Katerina A and Duffy, Joseph R and Clark, Heather M and Pham, Nha Trang Thu and Machulda, Mary M and Botha, Hugo and Jack, Clifford R and Dickson, Dennis W and Lowe, Val J and Josephs, Keith A and Whitwell, Jennifer L and Utianski, Rene L},
title = {Amyloid and Tau PET Positivity in Progressive Agrammatic Aphasia and Apraxia of Speech},
journal = {Journal of Alzheimer's Disease},
year = {2023},
doi = {10.3233/jad-230912}
}
EUVIMED